Truxima (rituximab) vs Tibsovo (ivosidenib)
Truxima (rituximab) vs Tibsovo (ivosidenib)
Truxima (rituximab) and Tibsovo (ivosidenib) are used to treat different types of cancer. Truxima is a monoclonal antibody that targets the CD20 protein found on the surface of B cells and is commonly used in the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia. In contrast, Tibsovo is a targeted therapy that inhibits the mutant IDH1 enzyme, which is found in certain cancers, and is indicated for the treatment of acute myeloid leukemia (AML) with a specific IDH1 mutation. When deciding on which medicine is right for an individual, it is essential to consider the specific type of cancer and its genetic characteristics, as well as the patient's overall health and treatment goals, since each medication is tailored to different disease mechanisms and indications.
Difference between Truxima and Tibsovo
| Metric | Truxima (rituximab) | Tibsovo (ivosidenib) |
|---|---|---|
| Generic name | Rituximab | Ivosidenib |
| Indications | Non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis | Acute myeloid leukemia (AML) with a specific genetic mutation (IDH1) |
| Mechanism of action | CD20-directed cytolytic antibody | Inhibitor of the isocitrate dehydrogenase-1 (IDH1) enzyme |
| Brand names | Truxima, Rituxan, MabThera | Tibsovo |
| Administrative route | Intravenous infusion | Oral |
| Side effects | Infusion reactions, fever, lymphopenia, chills, infection, and asthenia | Fatigue, leukocytosis, arthralgia, diarrhea, dyspnea, edema, nausea, mucositis, QT interval prolongation |
| Contraindications | Severe, active infections and severe immunocompromised states | Known hypersensitivity to ivosidenib or any of its components |
| Drug class | Monoclonal antibody | Enzyme inhibitor |
| Manufacturer | Celltrion Healthcare, Teva Pharmaceuticals, Genentech (Roche) | Agios Pharmaceuticals, Inc. |
Efficacy
Truxima (Rituximab) Efficacy in Leukemia
Truxima, a biosimilar to the original rituximab product, is a monoclonal antibody that targets the CD20 antigen found on the surface of B-cells. It is used in the treatment of non-Hodgkin lymphoma, which is a type of leukemia. The efficacy of rituximab for this indication has been demonstrated in numerous clinical trials, where it has been shown to improve survival rates when used in combination with chemotherapy. In chronic lymphocytic leukemia (CLL), rituximab has been used off-label and has shown to improve response rates and progression-free survival when combined with chemotherapy regimens like fludarabine and cyclophosphamide.
The use of Truxima in the treatment of leukemia is based on the ability of rituximab to bind to CD20, which leads to the destruction of B-cells, including malignant ones. This can result in reduced tumor burden and a delay in disease progression. However, the efficacy can vary depending on the stage of the disease, the specific characteristics of the leukemia, and the patient's overall health status.
Tibsovo (Ivosidenib) Efficacy in Leukemia
Tibsovo, or ivosidenib, is an oral medication approved for the treatment of acute myeloid leukemia (AML) with a specific genetic mutation known as isocitrate dehydrogenase-1 (IDH1). In clinical trials, Tibsovo has demonstrated efficacy in patients with relapsed or refractory AML with an IDH1 mutation. The drug works by inhibiting the mutant IDH1 enzyme, which is involved in the abnormal proliferation of leukemia cells.
The efficacy of Tibsovo in AML was highlighted in a pivotal Phase 1 study, where it showed a complete remission (CR) rate in a significant percentage of patients, with some patients also achieving partial remission. The median duration of CR was also notable, indicating a potentially durable response to the treatment. It is important to note that the efficacy of Tibsovo is specifically linked to the presence of the IDH1 mutation, and it is not indicated for AML patients without this genetic abnormality.
Regulatory Agency Approvals
Truxima
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
-
Health Canada
-
Therapeutic Goods Administration (TGA), Australia
-
Medsafe (NZ)
Tibsovo
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Access Truxima or Tibsovo today
If Truxima or Tibsovo are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us